Surf Therapeutics Reports Positive First-in-Human Data and Secures Additional Financing, Bringing Total Funding to $6M as Rheumatoid Arthritis Clinical Study Begins
Surf Therapeutics, a clinical-stage company developing non-invasive ultrasound neuromodulation therapies to treat immune-mediated diseases, today reported positive first-in-human study results and announced the close of an extension seed financing round, bringing the company’s total funding to approximately $6 million.
Surf Therapeutics Announces Early Feasibility Study (EFS) To Advance Non-Invasive Approach to Neuromodulation for Rheumatoid Arthritis
Surf Therapeutics, a clinical-stage neuro-immunomodulation company developing non-invasive ultrasound therapy for chronic inflammatory diseases, is announcing the start of an Early Feasibility Study evaluating its investigational ultrasound device in people living with rheumatoid arthritis. The study is designed to assess a non-invasive approach to activate a neural pathway that triggers a robust anti-inflammatory response, without the need for drugs, surgery, or an implanted device. Information about the study, including eligibility criteria and site locations, is available at ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07293871
